CLN2 Disease: Current Understandings, Challenges, and Future Directions

Area of Science:

• Neurology
• Genetics
• Pediatrics

Background:

• Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare, fatal neurodegenerative disorder in children.
• Characterized by rapid progression of language regression, motor decline, seizures, and vision loss.
• Enzyme replacement therapy (ERT) has emerged as a transformative treatment, necessitating early diagnosis.

Purpose of the Study:

• To review the current understanding of CLN2 disease.
• Focus on early clinical presentation, diagnostic challenges, and therapeutic advancements.
• Highlight the impact of ERT and future treatment prospects like gene therapy.

Main Methods:

• Literature review of CLN2 disease.
• Analysis of clinical presentation, diagnostic tools, and treatment outcomes.
• Exploration of emerging therapies and challenges in global access.

Main Results:

• Early clinical signs can be subtle, leading to diagnostic delays.
• ERT significantly alters the disease trajectory but cannot reverse established damage.
• Gene therapy shows promise but faces challenges in efficacy and delivery.

Conclusions:

• Early identification and intervention with ERT are critical for managing CLN2 disease.
• Addressing global access disparities and optimizing treatment strategies are essential.
• Continued research into gene therapy and biomarkers is needed for a potential cure.